8-K: Cardiff Oncology Presents Promising Preclinical Data at AACR, Bolstering Onvansertib's Potential in Multiple Cancers

Cardiff Oncology announced the presentation of five abstracts at the AACR annual meeting, highlighting the potential of onvansertib in treating various cancers, particularly RAS-mutated metastatic colorectal cancer.

Summary

• Cardiff Oncology presented five abstracts at the American Association for Cancer Research (AACR) annual meeting, showcasing preclinical and clinical data for their lead drug, onvansertib.
• The data supports onvansertib's potential in treating RAS-mutated metastatic colorectal cancer (mCRC), with a focus on its ability to inhibit tumor adaptation to hypoxia.
• In a Phase 1b/2 trial, bev naive patients treated with onvansertib plus FOLFIRI/bev showed a significantly higher response rate and longer progression-free survival compared to bev exposed patients.
• Preclinical data also indicates onvansertib's activity in RAS-wild type mCRC, small cell lung cancer (SCLC), and ovarian cancer, both as a single agent and in combination with other therapies.
• A Phase 2 trial (CRDF-004) is ongoing to evaluate onvansertib in combination with standard-of-care for first-line treatment of RAS-mutated mCRC, randomizing 90 patients into three arms with different doses of onvansertib or standard of care alone.

Sentiment

Score: 8

Explanation: The document presents very positive clinical and preclinical data, suggesting a strong potential for onvansertib. The focus on a novel mechanism of action and the high response rates in bev naive patients are particularly encouraging. However, the company is still in the clinical stage, so there is still risk.

Positives

• Onvansertib shows a strong efficacy signal in bev naive patients with RAS-mutated mCRC, supported by two independent datasets.
• The drug's ability to inhibit the hypoxia pathway is a novel mechanism that could enhance its effectiveness in combination with bevacizumab.
• Preclinical data suggests onvansertib has potential in multiple cancer types beyond RAS-mutated mCRC, including RAS-wild type mCRC, SCLC, and ovarian cancer.
• The ongoing Phase 2 trial (CRDF-004) is designed to confirm the optimal dose of onvansertib in first-line RAS-mutated mCRC treatment.

Risks

• The clinical trials are still ongoing, and the results are preliminary.
• The success of onvansertib in later-stage trials and in real-world settings is not yet guaranteed.
• The company is still in the clinical stage and may require additional funding to complete its development programs.

Future Outlook

Cardiff Oncology is focused on advancing its clinical programs for onvansertib, particularly the Phase 2 trial in first-line RAS-mutated mCRC, and exploring its potential in other cancer types.

Management Comments

• Mark Erlander, Ph.D., Chief Executive Officer of Cardiff Oncology, stated that the preclinical and clinical data presented at AACR is promising and validates their ongoing first-line RAS-mutated mCRC trial.
• He also highlighted the significantly greater clinical response in bev naive patients compared to bev exposed patients.

Industry Context

The announcement highlights the ongoing research and development in targeted cancer therapies, particularly in addressing treatment resistance and improving outcomes in metastatic colorectal cancer and other difficult-to-treat cancers. The focus on PLK1 inhibition and the hypoxia pathway aligns with current trends in oncology research.

Comparison to Industry Standards

• The reported 73% response rate in bev naive patients in the Phase 1b/2 trial is notably higher than typical response rates seen in second-line mCRC treatments, which often range from 10-30%.
• The use of patient-derived xenograft (PDX) models for preclinical testing is a common practice in oncology drug development, allowing for more accurate prediction of clinical efficacy.
• The combination of onvansertib with standard-of-care therapies like FOLFIRI/bev and FOLFOX/bev is a strategy employed by many companies to improve the effectiveness of existing treatments.
• The focus on overcoming treatment resistance, particularly in cisplatin-resistant SCLC and platinum-resistant ovarian cancer, is a key area of unmet need in oncology.

Stakeholder Impact

• Shareholders may view the positive data as a positive sign for the company's future prospects.
• Patients with RAS-mutated mCRC and other cancers may benefit from the development of onvansertib.
• Employees of Cardiff Oncology may be motivated by the positive results and the potential for the drug to make a difference.

Next Steps

• Cardiff Oncology will continue the Phase 2 trial (CRDF-004) to evaluate onvansertib in first-line RAS-mutated mCRC.
• The company will further analyze the data from the AACR presentations and potentially initiate additional studies based on the findings.
• The posters from the AACR presentations will be posted to the Scientific Presentations section of the Cardiff Oncology website.

Key Dates

Keywords

onvansertib, mCRC, RAS-mutated, colorectal cancer, PLK1 inhibitor, hypoxia, bevacizumab, SCLC, ovarian cancer, clinical trial, AACR